Home / About Peptonic / Management


Erik Sundquist

Erik Sundquist

Chief Executive Officer
25 years of leadership experience in food, medical device and medical aesthetics companies worldwide; Held executive positions in several global companies in these industries; Managed global brands, international business organisations and been involved in several MA’s. Entrepreneurial Advisor for international business acceleration, M&A assessment and fund raising in medical device field.
Erik on LinkedIn »

Dan Markusson

Dan Markusson

Chief Operating Officer
Extensive experience within Biotech industry including: Doxa AB and CerBio Tech AB.


Recent Comments

    All press releases on Spotlightstockmarket.com

    All published press releases from PEPTONIC medical is available on spotlightstockmarket.com.

    About us

    PEPTONIC Medical is an innovative Swedish pharmaceutical company developing and commercializing safe and effective products for the treatment of menopausal symptoms, such as vaginal atrophy. VagiVital® is a registered trademark of PEPTONIC Medical. The product is being commercialised for the non-prescription use for the treatment of vaginal atrophy.

    The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free oxytocin based product for the treatment of vaginal atrophy in clinical development phase 2.

    Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women.